Literature DB >> 28421340

Is tumor cellularity in primary invasive breast carcinoma of prognostic significance?

Emily S Reisenbichler1,2, William Dupont3, W Dale Plummer3, Omar Hameed4,5,6.   

Abstract

Many methods of analysis to predict survival of invasive mammary carcinoma in the post-neoadjuvant setting utilize tumor cellularity alone or in combination with other tumor features. The goal of this study was to evaluate the prognostic value of tumor cellularity in primary non-treated carcinoma. We used 366 cases of invasive breast carcinoma to determine invasive tumor cellularity (%) by reviewing a representative excisional tumor section and correlated this with breast cancer recurrence (BCR) and overall mortality (OM). Mean patient age was 58 years (range, 21-91) and median follow-up was 87 months (range, 0.7-165). Of the cases, 25% were Nottingham grades I, 41% grade II, and 32% grade III. The Nottingham Prognostic Index (NPI) ranged from 2.06 to 6.8 (mean 3.93). Estrogen receptor was positive in 66% and negative in 25% of cases. Cellularity ranged from 2 to 99% (mean 47.6%). The OM hazard ratio increased by 1.73 for every unit increase in NPI (P < 0.00005; 95% confidence interval 1.45-2.05) The BCR hazard ratio increased by 2.011 for every unit increase in NPI BCR (P < 0.00005; 95% confidence interval 1.62-2.50). Cellularity, unadjusted for other covariates, was not significantly associated with either OM or BCR. When adjusted for NPI, cellularity still showed no significant relation to OM or BCR. The same analysis performed on estrogen receptor-positive and estrogen receptor-negative subgroups continued to show no relation between cellularity and OM or BCR. In conclusion, despite its utility in the neoadjuvant setting, we were unable to show that cellularity is predictive of survival in primary breast carcinomas.

Entities:  

Keywords:  Breast carcinoma; Prognostic indicators; Tumor cellularity

Mesh:

Year:  2017        PMID: 28421340     DOI: 10.1007/s00428-017-2120-4

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  20 in total

1.  Reproducibility and validation of tumour stroma ratio scoring on oesophageal adenocarcinoma biopsies.

Authors:  Ewout F W Courrech Staal; Vincent T H B M Smit; Marie-Louise F van Velthuysen; Juliette M J Spitzer-Naaykens; Michel W J M Wouters; Wilma E Mesker; Rob A E M Tollenaar; Johanna W van Sandick
Journal:  Eur J Cancer       Date:  2010-10-29       Impact factor: 9.162

2.  The estimation of tumor cell percentage for molecular testing by pathologists is not accurate.

Authors:  Alexander J J Smits; J Alain Kummer; Peter C de Bruin; Mijke Bol; Jan G van den Tweel; Kees A Seldenrijk; Stefan M Willems; G Johan A Offerhaus; Roel A de Weger; Paul J van Diest; Aryan Vink
Journal:  Mod Pathol       Date:  2013-07-26       Impact factor: 7.842

3.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014.

Authors:  R Salgado; C Denkert; S Demaria; N Sirtaine; F Klauschen; G Pruneri; S Wienert; G Van den Eynden; F L Baehner; F Penault-Llorca; E A Perez; E A Thompson; W F Symmans; A L Richardson; J Brock; C Criscitiello; H Bailey; M Ignatiadis; G Floris; J Sparano; Z Kos; T Nielsen; D L Rimm; K H Allison; J S Reis-Filho; S Loibl; C Sotiriou; G Viale; S Badve; S Adams; K Willard-Gallo; S Loi
Journal:  Ann Oncol       Date:  2014-09-11       Impact factor: 32.976

4.  Reading the prognosis of the individual with breast cancer.

Authors:  R W Blamey; S E Pinder; G R Ball; I O Ellis; C W Elston; M J Mitchell; J L Haybittle
Journal:  Eur J Cancer       Date:  2007-02-22       Impact factor: 9.162

5.  Prognostic significance of the tumor-stroma ratio: validation study in node-negative premenopausal breast cancer patients from the EORTC perioperative chemotherapy (POP) trial (10854).

Authors:  T J A Dekker; C J H van de Velde; G W van Pelt; J R Kroep; J-P Julien; V T H B M Smit; R A E M Tollenaar; W E Mesker
Journal:  Breast Cancer Res Treat       Date:  2013-05-25       Impact factor: 4.872

6.  Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.

Authors:  W Fraser Symmans; Florentia Peintinger; Christos Hatzis; Radhika Rajan; Henry Kuerer; Vicente Valero; Lina Assad; Anna Poniecka; Bryan Hennessy; Marjorie Green; Aman U Buzdar; S Eva Singletary; Gabriel N Hortobagyi; Lajos Pusztai
Journal:  J Clin Oncol       Date:  2007-09-04       Impact factor: 44.544

7.  The stromal part of adenocarcinomas of the oesophagus: does it conceal targets for therapy?

Authors:  Ewout F W Courrech Staal; Michel W J M Wouters; Johanna W van Sandick; Marijn M Takkenberg; Vincent T H B M Smit; Jan M C Junggeburt; Juliette M J Spitzer-Naaykens; Tom Karsten; Henk H Hartgrink; Wilma E Mesker; Rob A E M Tollenaar
Journal:  Eur J Cancer       Date:  2010-01-13       Impact factor: 9.162

8.  Prognostic significance of tumour stroma ratio in inflammatory breast cancer.

Authors:  Candice L Downey; Helene H Thygesen; Nisha Sharma; Abeer M Shaaban
Journal:  Springerplus       Date:  2015-02-10

9.  The prognostic significance of tumour-stroma ratio in oestrogen receptor-positive breast cancer.

Authors:  C L Downey; S A Simpkins; J White; D L Holliday; J L Jones; L B Jordan; J Kulka; S Pollock; S S Rajan; H H Thygesen; A M Hanby; V Speirs
Journal:  Br J Cancer       Date:  2014-02-18       Impact factor: 7.640

10.  The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage.

Authors:  Wilma E Mesker; Jan M C Junggeburt; Karoly Szuhai; Pieter de Heer; Hans Morreau; Hans J Tanke; Rob A E M Tollenaar
Journal:  Cell Oncol       Date:  2007       Impact factor: 6.730

View more
  1 in total

1.  IL-33 in the tumor microenvironment is associated with the accumulation of FoxP3-positive regulatory T cells in human esophageal carcinomas.

Authors:  Guanglin Cui; Zhenfeng Li; Jingli Ren; Aping Yuan
Journal:  Virchows Arch       Date:  2019-05-06       Impact factor: 4.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.